HMOX1 and central nervous system cancer: Considering that patients with lower HMOX1 expression had lower TIDE score and showed higher response rate to immunotherapy, we conclude that HMOX1, as well as HMOX1-based risk signature, is capable for predicting the immunotherapy efficacy in lower grade gliomas.